PharVision Advisers’s Autoliv ALV Stock Holding History

PharVision Advisers’s Portfolio ALV Stock Details ALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,780	Closed	-$220K	–	683
2025 Q3	$220K	Buy	+1,780	New	+$213K	0.12%	428

Other funds holding ALV

CCI

Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's ALV Position: Q4 2025 in Review

PharVision Advisers sold out of Autoliv (ALV) in Q4 2025, closing a stake of 1,780 shares — an estimated $220K sold.

PharVision Advisers first reported a position in ALV in Q3 2025 and held it in 1 quarter. The position peaked at $220K in Q3 2025. 407 funds tracked by Wall St. Rank hold ALV as of Q4 2025.

PharVision Advisers reported no remaining Autoliv position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 1,780 Autoliv shares in Q4 2025, an estimated $220K.
PharVision Advisers first reported a position in Autoliv in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Autoliv position peaked at $220K in Q3 2025.
407 funds tracked by Wall St. Rank held Autoliv as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.